Functional Abdominal Pain Syndrome (FAPS): Beyond IBS, What Helps

If you have lived with chronic abdominal pain that does not behave like IBS, that does not respond to the usual diet and motility interventions, and that has been variously labelled as IBS, anxiety, or unexplained, this page is for you. Functional Abdominal Pain Syndrome (FAPS), now classified under Rome IV as Centrally Mediated Abdominal Pain Syndrome (CAPS), is a distinct condition with a distinct mechanism and a distinct treatment hierarchy. Recognising it correctly tends to be the single largest determinant of how well a patient does. We walk through the FAPS-vs-IBS distinction, the Rome IV criteria, the central-sensitisation mechanism that drives the pain, the appropriate diagnostic workup, the evidence ranking on treatments, where gut-directed hypnotherapy fits given that its evidence base is smaller in FAPS than in IBS, and a realistic protocol for living with the condition while improvement accumulates.

FAPS and IBS are both functional GI disorders, both are common, and both produce abdominal pain that brings patients to clinic. The similarities tend to obscure a clinically important difference. In IBS, abdominal pain is anchored to bowel function. The Rome IV criteria for IBS require recurrent abdominal pain associated with defecation and with a change in stool frequency or form. The pain rises and falls with the rhythms of digestion. It worsens before a bowel movement and often eases after. It tracks with eating in patterns the patient can usually describe. The biology is consistent with this picture: motility abnormalities, visceral hypersensitivity tied to gut distension and contraction, microbiome and gut-immune signalling shifts that all interact with the mechanics of digestion.

FAPS does not behave that way. The defining feature is that the pain is continuous or near-continuous, present in similar form whether the bowels have moved that day or not, not reliably triggered or relieved by eating, and not consistently associated with a change in stool form or frequency. The pain has its own rhythm, often described as a constant ache or burning with episodic flares, rather than a pattern locked to digestion. This decoupling is the diagnostic signature.

Rome IV, the most recent international classification of functional GI disorders, formalised this distinction by reclassifying FAPS as Centrally Mediated Abdominal Pain Syndrome (CAPS) in a separate category from IBS. The renaming was deliberate. It signalled to clinicians that the mechanism is centrally driven (in the central nervous system, specifically the spinal cord and brain pain-processing pathways) rather than peripherally driven by the gut itself. The implication for treatment is direct. Therapies that target peripheral mechanisms (low-FODMAP, antispasmodics, motility-targeted drugs, gut-acting laxatives) generally do not help FAPS patients much because the gut is not the primary problem. Therapies that target central pain processing (low-dose tricyclic antidepressants, SNRIs, cognitive behavioural therapy, brain-gut therapies including gut-directed hypnotherapy) have a much better fit with the underlying biology.

Many FAPS patients have spent years cycling through IBS treatments without meaningful response. The lack of response is sometimes interpreted as the patient being non-compliant, anxious, or somatising. The simpler and more accurate explanation is usually that they were on the wrong treatment hierarchy because the diagnostic label was wrong. Fixing the label tends to be a turning point. For a related discussion of conditions that get inappropriately swept under an IBS label, see the page on conditions misdiagnosed as IBS. For background on how the gut-brain pain amplification mechanism works in detail, see the page on the central sensitisation mechanism, which is the dominant biology underneath FAPS.

The pattern in clinic: how patients describe FAPS

FAPS patients in clinic describe their pain in characteristic ways. The pain is "always there." It does not have an obvious trigger. It does not let up after a bowel movement. It does not reliably worsen or improve with food. It can be present at the same intensity for weeks at a time, with intermittent flares that are sometimes provoked by stress, illness, sleep deprivation, or weather changes, but often arise without an identifiable trigger. The location is most commonly periumbilical (around the belly button) or diffusely across the upper or lower abdomen, though it can be focal. Patients often describe a burning, gnawing, aching, or dull pressure quality. Sharp or colicky pain is less typical and should prompt re-examination of the diagnosis.

The functional impact is often substantial. FAPS patients commonly miss work, restrict social activities, avoid travel, and develop secondary mood symptoms (anxiety and depression are over-represented in chronic pain populations and FAPS is no exception). Sleep is often disrupted. Many patients describe a long history of being told their tests are normal and that there is "nothing wrong," which compounds the distress. Recognising and naming the condition correctly is itself a meaningful intervention because it removes the implicit accusation of fabrication that comes with an unexplained pain label.

The Rome IV criteria are the international consensus framework for diagnosing functional GI disorders, used by gastroenterologists and primary care physicians around the world. For Centrally Mediated Abdominal Pain Syndrome, the criteria require all of the following to be met, with symptom onset at least six months before diagnosis and active symptoms over the most recent three months.

Continuous or nearly continuous abdominal pain. The pain is present most of the time, not in discrete episodes. There may be variation in intensity (a baseline level with periodic flares), but there is no sustained pain-free interval over weeks or months. Patients who can identify reliably pain-free days probably do not have FAPS.

No or only occasional relationship of pain to physiological events. The pain does not consistently track with eating, defecation, or menses. There may be incidental coincidence (a stressful day, a particularly stressful meal, a flare during a menstrual period) but the relationship is not the dominant pattern. If the pain reliably eases after a bowel movement or reliably worsens after meals, IBS or another functional disorder is more likely than FAPS.

Some loss of daily functioning. The pain is severe enough to interfere with work, school, social life, family responsibilities, sleep, or self-care. This is not a strict quantitative threshold, but the criterion exists to distinguish FAPS from incidental low-grade abdominal symptoms that do not affect quality of life.

The pain is not feigned. This is in the criteria explicitly because of the historical tendency of clinicians to assume severe unexplained pain on a normal workup must be malingering or factitious. The Rome IV authors included this clause to make clear that FAPS is a real diagnosis with real biology and that the assumption of feigning is not justified by normal investigations alone.

Insufficient criteria for other functional GI disorder. If the pain pattern fits IBS, functional dyspepsia, biliary pain, or one of the other Rome IV functional disorders better than CAPS, the more specific diagnosis takes precedence. CAPS is a residual category for patients whose pain syndrome does not fit elsewhere.

Symptom onset at least six months before diagnosis, active in the last three months. This duration requirement is important. It excludes acute and subacute pain, which deserve a different workup, and it captures the chronicity that defines the condition.

Why getting the right Rome IV label matters for treatment selection

The Rome IV system is not bureaucratic ceremony. The labels map onto different mechanisms and different evidence-based treatment hierarchies. An IBS label points the care team toward peripheral and brain-gut interventions appropriate to a motility-and-sensation disorder anchored in bowel function. A CAPS label points the team toward centrally acting strategies because the gut is not the primary problem. Functional dyspepsia points toward gastric-targeted approaches. Biliary functional disorders point toward gallbladder and sphincter-of-Oddi assessment. The cost of getting the label wrong is years of treatments aimed at the wrong mechanism, with predictable lack of response, and the secondary harm of patients losing faith in the system or being labelled treatment-resistant when the issue was diagnostic, not therapeutic.

Central sensitisation is the single most important concept for understanding FAPS. It is the mechanism that explains why the pain is severe, why it is persistent, why it is largely uncoupled from gut activity, and why peripheral interventions fail. Central sensitisation is also the mechanism shared with several other chronic pain syndromes that frequently overlap with FAPS, including fibromyalgia, chronic pelvic pain, vulvodynia, temporomandibular pain disorders, and chronic tension-type headache. Patients with FAPS are often surprised to learn that the same biology underlies all of these conditions and that they often co-occur.

In ordinary pain processing, a noxious stimulus at the periphery (a cut, a burn, a stretch on a tissue) generates an electrical signal that travels up sensory nerves to the spinal cord, gets relayed through interneurons, and ascends to the brain where it is processed and interpreted as pain. The system has many gating and modulating points along the way. Endogenous opioid systems can dampen the signal. Descending inhibitory pathways from the brainstem can quiet the spinal cord transmission. The brain can up-weight or down-weight the signal based on context, attention, mood, expectations, and prior experience.

In central sensitisation, this entire system has been recalibrated to a higher gain. Three specific phenomena dominate the picture.

Hyperalgesia is amplified pain in response to a normally painful stimulus. A pinch that would feel like a 3 out of 10 to a healthy person feels like a 7 out of 10 to a sensitised person. The mechanism is partly peripheral (sensitised nerve endings fire more vigorously) and partly central (the spinal cord and brain amplify the signal as it travels through them). In FAPS, hyperalgesia presents as severe pain in response to ordinary digestive sensations that would barely register in a non-sensitised gut.

Allodynia is pain in response to a non-painful stimulus. A light touch that would not normally hurt feels painful. Stretching of the gut wall by gas or by normal post-meal distension, which a healthy person would not consciously perceive at all, becomes a source of significant pain. Allodynia is the reason FAPS patients often experience pain at moments when there is nothing happening in the gut that would explain it.

Wind-up and central reorganisation. Repeated firing of pain signals over time changes the spinal cord and brain at a structural and functional level. Synaptic connections strengthen, the cortical representation of the painful region expands, descending inhibitory pathways become less effective, and the central pain-processing system becomes biased toward amplification. This is the reason chronic pain is so much harder to treat than acute pain: the nervous system has remodelled itself around the pain. Reversing that remodelling takes time and the right kind of input.

Brain imaging studies in FAPS and other central sensitisation syndromes consistently show altered activity in the anterior cingulate cortex, insula, prefrontal cortex, and thalamus during gut stimulation, with patterns that suggest both amplified incoming signals and reduced descending inhibition. The biology is real and measurable. It is not a metaphor for psychological distress, although psychological distress can amplify it and being in chronic pain reliably produces psychological distress.

For a deeper treatment of how the same mechanism shows up in IBS specifically (where it is one of several drivers rather than the dominant one), see the page on the central sensitisation mechanism and the related discussion of IBS mechanism overlap. The mechanisms cross-pollinate and many patients have features of both.

Why peripheral interventions usually fail in FAPS

If the dominant problem is in the central nervous system, interventions aimed at the gut itself have limited leverage. Antispasmodics, which relax gut smooth muscle, can help IBS patients who have a motility-and-cramping component. They generally do not help FAPS patients because the gut muscle is not the primary issue. Low-FODMAP diets, which reduce gas production and osmotic load on the gut, can help IBS patients who have a substantial bloating component. They generally do not help FAPS patients because the pain is not driven by intra-luminal contents. Motility-targeted drugs (loperamide, lubiprostone, linaclotide, prucalopride) help IBS patients with specific subtype problems. They have minimal effect on FAPS pain because the pain is not generated by motility patterns.

None of this is to say peripheral therapies are worthless in a FAPS patient who happens to also have a digestive component. Many patients have a mix of FAPS and IBS or FAPS and functional dyspepsia, and addressing the digestive components can take pressure off the system and reduce flare frequency. The framing is "address what is there, but do not expect peripheral therapies to be the main lever for the FAPS pain itself."

FAPS is a diagnosis of pattern, not a pure diagnosis of exclusion, but the structural workup still matters. The reason is that several treatable conditions can present with chronic abdominal pain that mimics FAPS, and missing them has serious consequences. The workup needs to be appropriate to the patient\'s age, history, and red-flag profile, but it generally includes some combination of the following.

Bloodwork to rule out inflammation, anaemia, electrolyte disturbances, and basic organ function. A complete blood count, comprehensive metabolic panel, C-reactive protein, erythrocyte sedimentation rate, and faecal calprotectin (a marker of bowel inflammation) are common starting points. Coeliac serology (anti-tissue transglutaminase IgA) is reasonable in most chronic abdominal pain workups.

Imaging when indicated by red flags or pattern. CT or MRI of the abdomen and pelvis can identify structural lesions, masses, vascular abnormalities, or chronic mesenteric ischaemia. Ultrasound is used for biliary, hepatic, renal, and gynecological pathology. Imaging is not routinely indicated for every FAPS workup but should be considered when clinical features point toward a structural cause.

Endoscopy and colonoscopy when indicated. These are not routinely required for FAPS but should be considered if there are red flags (weight loss, bleeding, anaemia, family history of colorectal cancer or inflammatory bowel disease, age over 50 with new symptoms, or persistent symptom change). The role is to rule out IBD, malignancy, and structural lesions.

Gynecological assessment in patients with cyclical features or pelvic component. Endometriosis, ovarian pathology, and pelvic inflammatory disease can all present with chronic abdominal or pelvic pain. A pelvic exam and a gynecological consult are appropriate when the pattern raises the question.

Targeted testing based on history. If the history suggests porphyria, hereditary angioedema, chronic pancreatitis, or another specific condition, targeted testing should be done. The aim is not to test for everything possible. The aim is to test for the conditions that the clinical picture actually raises, and to be confident the workup is sufficient before settling on the FAPS label.

Red flags that should prompt re-examination of the diagnosis

Even after a FAPS diagnosis is made, certain features should prompt the care team to reopen the workup. New unexplained weight loss. Rectal bleeding or melena. Iron deficiency anaemia. Nocturnal pain that wakes the patient. Fever. A change in pain character or location. Persistent vomiting. Jaundice. New onset of symptoms after age 50. A first-degree relative with colorectal cancer or inflammatory bowel disease who has not been screened. None of these features are diagnostic of a specific alternative condition, but they are reasons to step back from the FAPS label and look harder before accepting it as the answer.

The drug-seeking accusation: why FAPS patients keep encountering it

One of the most painful experiences described by FAPS patients is being treated as drug-seeking when they ask for help with severe pain. The pattern is depressingly consistent. The patient describes severe chronic pain. The investigations come back normal. The patient asks about pain relief options. The clinician, often without realising they are doing it, becomes guarded and starts looking for evidence of opioid-seeking behaviour. The interaction becomes adversarial. The patient leaves feeling accused, the clinician feels confirmed in their suspicion that the pain is exaggerated, and the relationship deteriorates.

The structural drivers of this pattern are worth naming because understanding them helps patients navigate around them. The opioid crisis has made every chronic pain patient a candidate for suspicion in the eyes of clinicians who were trained in or after the era of opioid-prescribing crackdowns. Severe pain on a normal workup is, on its surface, the textbook profile that prescribing-restraint training warns about. Most clinicians have never been formally taught that FAPS exists as a distinct diagnosis with its own evidence-based treatment hierarchy that does not include opioids. The result is a real and consistent pattern of FAPS patients being misread as drug-seeking when they are actually seeking competent care.

The practical implication for patients is that the path forward usually requires getting the diagnosis confirmed by a gastroenterologist (ideally one with experience in functional GI disorders), being explicit with the GP that you are not seeking opioids and that you understand opioids are contraindicated in chronic visceral pain, and asking for the evidence-based treatment hierarchy: low-dose tricyclic antidepressants, SNRIs in selected cases, brain-gut therapies, and possibly a pain-medicine consult for a coordinated chronic-pain approach. This framing tends to defuse the drug-seeking suspicion quickly because it signals that you are aware of the actual treatment pathway and are not chasing the wrong medication class.

The treatment hierarchy for FAPS is genuinely different from the IBS hierarchy because the dominant mechanism is different. Here is what the evidence supports, ranked by strength of evidence and typical clinical positioning.

Tier 1: Low-dose tricyclic antidepressants

Low-dose tricyclic antidepressants (amitriptyline, nortriptyline, desipramine, imipramine) are the strongest single-medication evidence base for centrally mediated abdominal pain. The evidence comes from multiple randomised trials and decades of clinical experience in chronic visceral and somatic pain syndromes. The mechanism is central pain modulation through enhanced descending inhibition (serotonergic and noradrenergic effects) and reduced central pain amplification, not the antidepressant effect at the higher mood-treatment doses. The doses used for pain are much lower (typically 10 to 50 mg at bedtime) than the doses used for major depression (often 75 to 150 mg or higher), and the analgesic effect is independent of any mood improvement.

Practical points. Start low (often 10 to 25 mg of amitriptyline or nortriptyline at bedtime) and titrate slowly to the lowest effective dose. Allow 4 to 8 weeks at a stable dose to assess response. Common side effects at these doses include morning grogginess, dry mouth, mild constipation (sometimes a feature, sometimes a problem depending on the patient\'s baseline), and occasional weight gain. Nortriptyline tends to be better tolerated than amitriptyline by older patients because it has fewer anticholinergic effects. Once a meaningful response is established, maintenance is usually 6 to 12 months, with a reassessment of whether the medication can be tapered after stable improvement.

Tier 1-2: SNRIs (duloxetine, venlafaxine)

Serotonin-norepinephrine reuptake inhibitors, particularly duloxetine, have a growing evidence base in chronic functional pain syndromes including FAPS. Duloxetine has formal indications for fibromyalgia, chronic musculoskeletal pain, and diabetic peripheral neuropathy, all of which share central sensitisation biology with FAPS. The trial data specifically in FAPS is smaller than the data for tricyclics but is moving in the same direction. SNRIs are often used when tricyclics have not been tolerated, when the patient has a substantial concurrent depression or anxiety component that would also benefit from treatment, or as an add-on when partial response to a tricyclic plateaus.

Tier 2: Cognitive behavioural therapy

Cognitive behavioural therapy adapted for chronic pain and for functional GI disorders has a substantial evidence base. The IBS-specific CBT trials are stronger than the FAPS-specific trials, but the overlap in mechanism (central sensitisation, attention to gut signals, catastrophising, activity avoidance, sleep disruption, mood comorbidity) means the techniques are largely transferable. Everitt 2019 (PMID 30765267), a large UK randomised trial, showed that CBT delivered by trained therapists produced clinically significant IBS symptom improvement in 71% of patients and is now in NICE and BSG guidelines as a recommended option for IBS. The same study and parallel literature support CBT as a reasonable option in FAPS as well, particularly when delivered by therapists with experience in chronic pain or functional GI disorders.

Tier 2: Gut-directed hypnotherapy and brain-gut therapies

Gut-directed hypnotherapy (GDH) on the Manchester Protocol has a strong evidence base in IBS and a smaller, mechanistically aligned evidence base in chronic functional pain syndromes more broadly. Miller 2015 (PMID 25736234) reported 76% response in 1,000 consecutive refractory IBS patients. Peters 2016 (PMID 27397586) showed equivalent symptom relief between GDH and a low-FODMAP diet in a randomised trial. Hasan 2019 (PMID 30702396) showed that 76% of GDH responders maintained their improvement at 5+ year follow-up, compared with 65% in a medical-management comparison group, suggesting durability that exceeds most other IBS interventions.

The honest framing for FAPS specifically is that the IBS evidence base is robust and the FAPS-specific evidence base is smaller. The mechanism overlap is strong: central sensitisation is the dominant FAPS driver, GDH targets central pain processing, and the techniques used in the Manchester Protocol (relaxation, imagery, suggestion focused on gut sensation and pain modulation) are mechanistically appropriate for the FAPS picture. Practitioners with experience in chronic pain and functional GI disorders increasingly use GDH as an adjunct in FAPS care, often alongside a low-dose tricyclic, with realistic framing about evidence depth.

Tier 3: Other centrally acting agents under specialist guidance

Several other agents have a place in selected FAPS patients under specialist guidance. Low-dose atypical antipsychotics (quetiapine, olanzapine) are sometimes used when there is a substantial sleep and pain component. Alpha-2-delta ligands (gabapentin, pregabalin) are sometimes tried when the pain has a neuropathic quality. Mirtazapine is occasionally used for the combined effect on sleep, appetite, mood, and visceral hypersensitivity. None of these are first-line, and all of them should be initiated in coordination with a physician familiar with chronic pain management or functional GI disorders.

Things that do not work well or actively harm in FAPS

NSAIDs (ibuprofen, naproxen, celecoxib) provide minimal benefit because FAPS is not primarily an inflammatory condition, and they can worsen gut symptoms by irritating the lining and increasing dyspepsia and bleeding risk.

Opioids are actively harmful. Beyond the dependence and tolerance issues familiar from chronic pain medicine, opioids in chronic visceral pain produce two specific problems. They slow gut motility dramatically, causing constipation and worsening abdominal symptoms. Prolonged use can produce opioid-induced hyperalgesia and a related entity called narcotic bowel syndrome, where the patient\'s abdominal pain paradoxically intensifies on the medication and improves when it is withdrawn.

Antispasmodics alone (dicyclomine, hyoscine, peppermint oil capsules) target gut smooth muscle. They can be useful in IBS where motility-and-cramping is part of the picture. They generally do not help FAPS pain because the pain is not driven by smooth muscle activity.

Restrictive diets pursued indefinitely. Low-FODMAP, gluten-free, dairy-free, and other elimination strategies can be reasonable to trial for several weeks if there is a question about a digestive overlay, but indefinite restriction in a patient whose pain is centrally driven adds nutritional risk and quality-of-life cost without a corresponding benefit on the FAPS pain.

Gut-directed hypnotherapy on the Manchester Protocol is a structured 8-to-12-session intervention developed at Whorwell\'s clinic in Manchester for IBS, with a substantial body of evidence in IBS specifically. The applicability to FAPS is mechanistic rather than directly trial-supported at the same scale, and the framing on this page reflects that distinction.

The IBS evidence base, in brief

The IBS evidence is robust. Miller 2015 (PMID 25736234) is the largest single-clinic case series in the field: 76% response in 1,000 consecutive refractory patients, with response defined as at least 50% improvement on a validated symptom score. Peters 2016 (PMID 27397586) is a randomised trial showing equivalent symptom relief between GDH and a low-FODMAP diet, with both arms producing clinically meaningful improvement and no statistically significant difference between them at 6-month follow-up. Hasan 2019 (PMID 30702396) is the durability anchor: 76% of GDH responders maintained their improvement at 5+ year follow-up compared with 65% in a medical-management comparison group, which is unusual in the IBS literature where most interventions regress over months. Everitt 2019 (PMID 30765267) sits alongside as the corresponding evidence anchor for cognitive behavioural therapy in IBS, with 71% of patients showing clinically significant improvement in the ACTIB trial, and both CBT and GDH are now in NICE and BSG guidelines as evidence-based brain-gut therapies for IBS.

What this means for FAPS specifically

FAPS-specific randomised trials of GDH at the scale of the IBS literature do not exist. There are smaller studies and clinical case series in chronic functional pain syndromes that share the central-sensitisation profile, and there is a strong mechanistic argument: GDH explicitly targets central pain processing, which is the dominant FAPS driver. Practitioners with experience in functional GI disorders increasingly use GDH as an adjunct in FAPS care, often alongside a low-dose tricyclic, with realistic framing about the evidence depth.

The honest position on this question matters. The wrong framing is "GDH cures FAPS." There is no trial that supports that claim and the practitioners who use it are overpromising. The wrong framing is also "GDH does not work for FAPS." That overstates the negative case because the mechanism aligns and clinical experience in carefully selected patients is reasonably positive. The defensible framing is "reasonable to try given mechanism overlap, especially as an adjunct, with realistic expectations about evidence depth and timeline." Patients who go in with that framing tend to use the intervention well. Patients who go in expecting rapid cure tend to abandon it before any benefit accumulates.

How GDH is typically delivered

The Manchester Protocol structure is 8 to 12 weekly sessions of about 50 to 60 minutes each. Sessions involve relaxation induction, imagery work focused on gut sensation and pain modulation, suggestion targeted at central pain processing pathways, and home practice between sessions using audio recordings. A standard initial commitment in many clinics is 3 sessions to assess fit and early response, with continuation if the patient is responding. Continuation beyond the initial commitment is optional. Outcomes are typically evaluated at the end of the 8-to-12-week course and again at 6 months.

For background on the evidence base in IBS and how the protocol is structured, see the page on GDH for IBS (related evidence base). For the stress and pain axis that overlaps with both IBS and FAPS biology, see the page on the stress-pain-axis overlap. The cortisol material is relevant in FAPS too, because chronic stress amplifies central sensitisation and lowering chronic stress load is one of the levers that supports the central pain-processing system in returning toward baseline.

Getting the FAPS label right is not a formality. Misapplied, it anchors the patient on a treatment hierarchy that does not fit their actual condition and delays effective management of whatever else is going on. The following framing helps clarify when FAPS is the right call and when it is not.

FAPS is likely the right diagnosis when

The pain is continuous or near-continuous and has been so for at least six months. The pain is largely uncoupled from bowel movements and from eating (incidental coincidence is allowed; consistent association is not). The structural workup appropriate to your age, history, and red-flag profile has been negative. The pain pattern fits Rome IV CAPS criteria better than IBS, functional dyspepsia, biliary pain, or another specific functional GI disorder. There is no red flag (weight loss, bleeding, anaemia, fever, jaundice, nocturnal pain that wakes you, family history of IBD or colorectal cancer that has not been screened) that has not been addressed. A gastroenterologist with experience in functional GI disorders has confirmed the pattern.

FAPS is likely the wrong diagnosis when

The pain is reliably linked to bowel function (worsens before defecation, eases after, tracks with stool form changes). IBS is more likely. The pain is reliably linked to eating, particularly to fatty meals or specific food categories. Functional dyspepsia or food sensitivity is more likely. The pain is sharp, colicky, or post-prandial in a pattern suggesting biliary or pancreatic origin. A biliary or pancreatic workup is appropriate. The pain is in a specific location that fits a structural cause (right lower quadrant pointing at appendix or ileal region, periumbilical pointing at small bowel obstruction or ischaemia, suprapubic pointing at urinary or gynecological origin). Structural workup is appropriate. There are red flags. Reopen the workup.

The role of the gastroenterologist in confirming the label

FAPS is one of the conditions where a specialist consultation is genuinely valuable, not just a procedural box. A gastroenterologist with experience in functional GI disorders can confirm that the pattern fits Rome IV CAPS criteria, that the workup is sufficient, and that the treatment hierarchy is being applied in the right order. Starting central pain modulators or brain-gut therapy on a self-diagnosed FAPS label without that confirmation is a meaningful mistake because it can either delay diagnosis of a treatable structural cause or anchor an inaccurate label that makes later reassessment harder.

Once the diagnosis is confirmed, the treatment plan can be coordinated between your GP, the gastroenterologist, and any adjunctive providers (chronic pain specialist, brain-gut therapist, hypnotherapist, mental-health clinician for any concurrent mood symptoms) involved in the layered plan. The GP is usually the right person to manage the day-to-day medication titration once the plan is established.

Treatment is the medical layer. Living with FAPS while improvement accumulates requires another layer that addresses pacing, sleep, stress regulation, validation, and the long arc of central nervous system recalibration. None of these substitute for evidence-based medical care, but they reliably improve outcomes when added to it.

Pacing: titrate activity to avoid pain spirals

Chronic pain patients commonly oscillate between two patterns. On low-pain days, they push hard to catch up on everything they have missed. On high-pain days, they crash. The boom-and-bust cycle reliably worsens central sensitisation because the periodic overload reinforces the pain signal and the periodic crash reinforces the avoidance. Pacing breaks the cycle by titrating activity to a sustainable baseline that does not provoke spirals. The technique is to identify the activity level that is reliably tolerable on most days, hold near that level even on good days, and increase the baseline gradually as tolerance grows. Most chronic pain rehabilitation programs teach pacing as a core skill because the evidence on its effect is robust.

Sleep priority: poor sleep amplifies central pain signals

Sleep quality and central pain processing are tightly coupled. Poor sleep amplifies pain perception, increases central sensitisation, and worsens the descending inhibitory pathways that normally quiet pain signals. Several FAPS treatments (low-dose tricyclics, mirtazapine) have sleep benefits as a secondary feature, which is not coincidental. The general approach is to protect sleep aggressively: a consistent sleep schedule, a wind-down routine that reduces evening cortisol and arousal, a cool dark sleep environment, attention to caffeine and alcohol timing, and a low threshold for treating concurrent insomnia or sleep apnea if those are present. Patients who fix their sleep often see meaningful improvement in pain even before the pharmacologic and brain-gut therapies have fully kicked in.

Stress regulation: the cortisol-pain connection is real

Chronic stress and the resulting cortisol dysregulation amplify central sensitisation through several mechanisms including effects on pain pathway plasticity, descending inhibitory pathway function, and immune signalling. Lowering chronic stress load is one of the levers that helps the central pain processing system return toward baseline. Practical strategies that are well-supported include slow diaphragmatic breathing practice, regular moderate aerobic exercise dosed at a level that does not provoke flares, mindfulness-based interventions adapted for chronic pain, and treatment of any concurrent anxiety or depression. For more on the cortisol mechanism in functional GI conditions, see the page on the stress-pain-axis overlap.

Validation: being believed is part of the treatment

One of the most consistent findings across the chronic functional pain literature is that patients who feel believed by their care team do better than patients who feel dismissed. This is not a soft observation. The mechanism is that feeling dismissed activates threat-processing circuits and reinforces the central sensitisation, while feeling believed and supported activates safety-processing circuits and supports the descending inhibitory pathways that quiet pain. Building a small care team of clinicians who take the diagnosis seriously, name it correctly, and do not imply drug-seeking is itself a clinical intervention, not just a comfort.

FAPS patients often have to advocate for this care team explicitly because the structural pressures on the system push toward dismissal. The practical implication is that it is reasonable to switch primary care physicians or gastroenterologists when the relationship is consistently dismissive, and it is reasonable to seek out clinicians with explicit experience in functional GI disorders when the local options are limited. This is not patient unreasonableness. This is matching care to a condition that does not behave the way the textbook usually expects.

The long arc: meaningful improvement over months, not days

Realistic expectations matter. The condition took months or years to install itself, the central sensitisation that drives it does not unwind in a few sessions, and the medications work on a timescale of weeks. The expected arc for a patient on a layered plan is meaningful improvement over 3 to 12 months, with continued gradual gains in the year after that. Patients who are warned about this timeline tend to do better than patients who are not, partly because they do not abandon effective treatments before they have had time to work, and partly because the longer view reduces the pressure of needing each week to show progress.

A note on insurance coverage in Canada

Hypnotherapy is generally not directly covered under Canadian extended health benefit plans. Some clients can claim related programs (stress management, behavioural change) under a Wellness Spending Account (WSA) if their plan offers one. Coverage rules depend entirely on plan design, so check with your insurance provider before booking. Sessions at this practice are paid at time of service. A detailed receipt is provided with the practitioner\'s ARCH registration number that you can submit for any reimbursement your provider may approve.

Practical service details

Sessions are delivered as gut-directed hypnotherapy on the Manchester Protocol, both virtually across Canada and in-person in Calgary, Alberta. Per-session fee is $220 CAD. Standard initial commitment is 3 sessions ($660 CAD total) which gives a reasonable window to assess fit and early response. Continuation beyond the initial 3 sessions is optional. Same price virtual or in-person, no admin fees. Conditions treated include IBS (all subtypes), SIBO as adjunct to medical treatment, functional dyspepsia, post-infectious IBS, visceral hypersensitivity, IBS with anxiety overlap, and chronic functional abdominal pain syndromes including FAPS as an adjunct to coordinated medical care.